| Name | Title | Contact Details |
|---|
Johnson and Johnson Vision Care is a company committed to transforming the world's vision. Since our inception, we have strived to increase awareness of the importance of vision and vision care and to provide the world's most exceptional vision correction
We are on the leading edge of research, development, clinical trials, and implementation of digital solutions that are aimed at harm reduction for various public health challenges. Our goal is to reduce harm and prevent unintentional deaths for people of all ages. Our team has pioneered apps that were developed in response to the opioid crisis, which is now a world-wide problem, as well as the COVID-19 pandemic and health & safety concerns in senior care centers.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Sleep is essential and Ebb Therapeutics is working tirelessly to provide a clinically-proven, FDA-cleared device for the treatment of insomnia that is safe and effective for use every night -- without side effects.
Caloptima Health Partnership is a Orange, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.